Document:

Exhibit 10.1

 

 

 

 

 

 

 

Dated
the 1st day of January 2018

 

AU,
SIK KEE (區錫機)

 

AND

 

REGENCELL
BIOSCIENCE LIMITED 

(腦再生科技有限公司)

_______________________________________________________

 

DEED OF
RIGHTS TRANSFER, STRATEGIC PARTNERSHIP AND UNDERTAKING

_______________________________________________________

 

 

 

 

 

 

 

 

     

     

    

 

This DEED
OF RIGHTS TRANSFER, STRATEGIC PARTNERSHIP AND UNDERTAKING is made on the 1st day of January 2018

 

BETWEEN

 

AU, SIK
KEE (區錫機), the holder of Hong Kong Identity Card No.
K*******, of 22/F, First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong, being the Listed Chinese Medicine
Practitioner with the Listed No. of L***** maintained by the Chinese Medicine Practitioners Board of the Chinese Medicine Council
of Hong Kong (“The Chinese Medicine Practitioner”);

 

AND

 

REGENCELL
BIOSCIENCE LIMITED (腦再生科技有限公司),
a company incorporated in Hong Kong as a private company with limited liability with the Company no. 2236362, whose registered
office and whose principal place of business in Hong Kong is 21/F, EIB Tower, 4-6 Morrison Hill Road, Wan Chai, Hong Kong (“Regencell”);

 

(collectively,
referred hereunder as to “the Parties”)

 

WHEREAS:-

 

		A.	The
                                         Chinese Medicine Practitioner is the founder, creator and developer of certain Traditional
                                         Chinese Medicine (“TCM”) formulae which can provide effective solutions
                                         for patients suffering from Attention Deficit and Hyperactivity Disorder (“ADHD”)
                                         and Autism Spectrum Disorders (“ASD”), which are supported by the
                                         research data of over 100 patients who suffered from ADHD and ASD , and all other TCM
                                         formulae targeting different kinds of human illnesses and diseases (collectively, “the
                                         TCM Formulae”), as well as all of the Intellectual Property Rights (as defined
                                         hereinunder) (collectively, “the TCM Formulae and All Intellectual Property
                                         Rights”).

 

		B.	The
                                         Chinese Medicine Practitioner is also the sole legal and beneficial owner of the intellectual
                                         property rights of the TCM Formulae, including research and development, trademark, copyright,
                                         patent, and any other intellectual property rights, whether registered, unregistered,
                                         registrable, unregistrable or otherwise, in relation to and/or in connection with the
                                         TCM Formulae (“the Intellectual Property Rights”).

 

    2

     

    

 

		C.	Regencell
                                         was incorporated in Hong Kong as a private limited company on 12th May 2015,
                                         with an objective to provide and further research and development of TCM Formulae and
                                         All Intellectual Property Rights to be sold and marketed commercially around the world.

 

		D.	By
                                         entering into this Deed, both The Chinese Medicine Practitioner and Regencell acknowledge
                                         that they have read and understood the matters set out herein and that they are of lawful
                                         and legally competent to execute this Deed. Both The Chinese Medicine Practitioner and
                                         Regencell further acknowledge that they understand and have been advised of their respective
                                         right to obtain independent legal advice before entering into this Deed and are aware
                                         of its legal implication.

 

		E.	The
                                         Parties acknowledge that the terms and conditions set out in this Deed are contractual
                                         in nature and they are intended to have legal effect and are not merely a warning or
                                         recital.

 

		F.	The
                                         Parties confirm that they enter into this Deed out of its/his own free will without any
                                         undue influence, pressure, representation or inducement by any others.

 

		G.	The
                                         Parties have agreed to enter into this Deed for The Chinese Medicine Practitioner to
                                         effect the transfer of ownership of the TCM Formulae and All Intellectual Property Rights
                                         and the TCM Inventions (as defined hereinafter) to Regencell and for Regencell to give
                                         an undertaking to The Chinese Medicine Practitioner in accordance with the terms set
                                         out in this Deed.

 

NOW THIS
DEED WITNESSES that: -

 

		1.	INTERPRETATION

 

		1.1	In
                                         this Deed, words importing the singular include the plural and vice versa, words importing
                                         gender or the neuter include both genders and the neuter and references to persons include
                                         bodies corporate or unincorporated.

 

		1.2	In
                                         this Deed, headings are for convenience only and shall not affect the construction of
                                         this Deed.

 

    3

     

    

 

		1.3	In
                                         construing this Deed:-

 

		(a)	the
                                         rule known as the ejusdem generis rule shall not apply and accordingly general words
                                         introduced by the word “other” shall not be given a restrictive meaning by
                                         reason of the fact that they are preceded by words indicating a particular class of acts,
                                         matters or things; and

 

		(b)	general
                                         words shall not be given a restrictive meaning by reason of the fact that they are followed
                                         by particular examples intended to be embraced by the general words.

 

		2.	TRANSFER
                                         OF OWNERSHIP OF TCM FORMULAE AND ALL INTELLECTUAL PROPERTY RIGHTS

 

		2.1	The
                                         Chinese Medicine Practitioner hereby irrevocably agrees that he shall assign all his
                                         legal and beneficial ownership in relation to and/or in connection with the TCM Formulae
                                         and All Intellectual Property Rights to Regencell upon execution of this Deed (“the
                                         Transfer”).

 

		2.2	In
                                         consideration of the Transfer, Regencell undertakes to The Chinese Medicine Practitioner
                                         and agrees to donate three percent (3.0%) of net revenue generated in association with
                                         the use and/or commercialization of the TCM Formulae and All Intellectual Property Rights
                                         (“the Donation”) upon the Transfer to any of the charitable institutions
                                         and/or trusts of a public character anywhere in the world (“the Charitable Organization”)
                                         at the sole and absolute choice of the Chinese Medicine Practitioner (or someone assigned
                                         by him in writing) and in such proportion at the sole and absolute discretion of the
                                         Chinese Medicine Practitioner (or someone assigned by him in writing) on a yearly basis.

 

		2.3	Regencell
                                         agrees that the calculation of the Donation will be relied on the net revenue as shown
                                         in the breakdown of the audited financial accounts of Regencell and The Chinese Medicine
                                         Practitioner is at his liberty to request Regencell to submit the audited financial accounts
                                         for his inspection at any time.

 

		2.4	Regencell
                                         agrees that for proving the compliance of its obligation under the clause 2.2 hereof,
                                         Regencell shall submit all payment slips regarding its Donation to the Charitable Organizations
                                         on a yearly basis or as requested by The Chinese Medicine Practitioner.

 

    4

     

    

 

		2.5	Regencell
                                         undertakes to pay for all costs and expenses incurred by the Chinese Medicine Practitioner
                                         in conducting research, testing, attending meetings/seminars, compiling records/reports
                                         or performing any similar acts in relation to the development of the TCM Formulae.

 

		2.6	Upon
                                         the execution of this Deed, The Chinese Medicine Practitioner acknowledges that the legal
                                         and beneficial ownership of the TCM Formulae and All Intellectual Property Rights shall
                                         vest and continue to vest in Regencell. Any products or services further developed by
                                         the use of the TCM Formulae and All Intellectual Property Rights or acquired thereunder
                                         shall remain the exclusive property of Regencell.

 

		2.7	The
                                         Chinese Medicine Practitioner shall do and perform or procure to be executed, done and
                                         performed by Regencell all such further acts, agreements, assignments, assurances, deeds
                                         and documents upon the request from Regencell to vest effectively the legal and beneficial
                                         ownership of the TCM Formulae and All Intellectual Property Rights in Regencell.

 

		3.	STRATEGIC
                                         PARTNERSHIP

 

		3.1	Regencell
                                         hereby forms a strategic partnership with The Chinese Medicine Practitioner whereas Regencell
                                         undertakes to continuously carry out its obligation under Clause 2.2 and The Chinese
                                         Medicine Practitioner accepts Clause 3.2 and Clause 3.3.

  

    5

     

    

  

		3.2	Any
                                         inventions, TCM formulae, utilities, models improvements, research, discoveries, designs,
                                         processes, methods of manufacture, distribution or management, products, works of authorship,
                                         creations and the like, including all of their Intellectual Property Rights, conceived
                                         or made by The Chinese Medicine Practitioner, either individually or jointly with others,
                                         and in relation to TCM (individually, an “TCM Invention”, and collectively,
                                         “TCM Inventions”), shall be the sole and exclusive property of Regencell,
                                         its successors, assigns and nominees, without any compensation in addition to that set
                                         forth in this Deed. The Chinese Medicine Practitioner is, however, permitted to continue
                                         to use or make use of the TCM Inventions solely in his practice and for his research
                                         as a Chinese Medicine practitioner. Without limiting the generality of the foregoing:

 

If
after the execution of this Deed, The Chinese Medicine Practitioner, either individually or jointly with others, conceives, authors,
makes or first actually reduces to practice any TCM Invention, The Chinese Medicine Practitioner shall promptly disclose to Regencell
full details thereof, including without limitation any notes, recipes, formulae, drawings and models relating thereto, and agrees
to assign and does hereby assign and transfer to Regencell, its successors, assigns and nominees, all The Chinese Medicine Practitioner’s
right, title and interest in and to such TCM Invention. At the expense and request of Regencell at any time and from time to time,
The Chinese Medicine Practitioner shall execute and deliver all documents and do all things necessary or desirable to enable Regencell,
its successors, assigns and nominees, to obtain the full benefit of an entire right, title and interest in and to such TCM Invention,
and to obtain, maintain, defend and enforce patent or other appropriate forms of protection for such TCM Invention throughout
the world, including without limitation the execution of all necessary applications, declarations, affidavits and other documentation.
All decisions as to the patenting and exploitation of any such TCM Invention shall be in the sole discretion of Regencell. The
Chinese Medicine Practitioner irrevocably appoints Regencell to be The Chinese Medicine Practitioner’s attorney-in-fact,
in The Chinese Medicine Practitioner’s name and on The Chinese Medicine Practitioner’s behalf, to execute and deliver
such documents or instruments and do all such things that are necessary or desirable for the purpose of giving to Regencell, its
successors, assigns and nominees the full benefit of the provisions of this Clause 3.2.

 

		3.3	The
                                         Chinese Medicine Practitioner shall promptly disclose to Regencell all works in which
                                         copyright or design right exists which are originated, conceived, written or made by
                                         The Chinese Medicine Practitioner, either individually or jointly with others, and shall,
                                         until such rights are fully and absolutely vested in Regencell, its successors, assigns
                                         and nominees, hold them in trust for Regencell. The Chinese Medicine Practitioner agrees
                                         to assign and does hereby assign and transfer to Regencell, its successors, assigns and
                                         nominees, all copyright, design right and other proprietary and/or intellectual property
                                         rights, if any, therein for the full terms thereof throughout the world. At the expense
                                         and request of Regencell at any time and from time to time, The Chinese Medicine Practitioner
                                         shall execute and deliver all documents and do all things necessary or desirable to enable
                                         Regencell, its successors, assigns and nominees, to obtain the full benefit of an entire
                                         right, title and interest in and to such rights, and to secure copyright or other forms
                                         of intellectual property protection for them throughout the world, and otherwise to establish
                                         and substantiate the rights of Regencell under this Clause 3.3.

 

    6

     

    

 

		4.	DISCLOSURE
                                         OF THIS DEED

 

		4.1	This
                                         Deed and/or any of the terms and conditions herein may be disclosed partially or entirely
                                         by either of the Parties for and only for the following purposes (“the Disclosure”).

 

		4.1.1	where
                                         the Disclosure, in the opinion of Regencell, is of use in promoting, marketing and commercializing
                                         the business of Regencell and/or the TCM Formulae and All Intellectual Property Rights
                                         to all potential investors.

 

		4.1.2	where
                                         the Disclosure, in the opinion of Regencell, is necessary to demonstrate and prove its
                                         legal and beneficial ownership of the TCM Formulae and All Intellectual Property Rights.

 

		4.1.3	where
                                         the Disclosure is required by law, by a court of competent jurisdiction or by another
                                         appropriate governmental, supervisory or regulatory body, within the extent permitted
                                         by law.

 

		5.	GENERAL

 

		5.1	The
                                         Parties represent and warrant that this Deed is executed on their behalf with full authorization
                                         and power and they are entitled to take any necessary measures to perform this Deed.

 

		5.2	No
                                         variation or amendment to this Deed shall be effective unless in writing and signed by
                                         the authorised representatives of all the Parties.

 

		5.3	Any
                                         provisions of this Deed held invalid or unenforceable shall not affect the enforceability
                                         of the other provisions that shall remain valid.

 

    7

     

    

 

		6.	TRANSFER
                                         OF BENEFIT

 

		6.1	The
                                         Chinese Medicine Practitioner agrees that Regencell can transfer this Deed, on the same
                                         terms and conditions, to Regencell’s successors, assigns and nominees as may from
                                         time to time be requested by Regencell.

 

		7.	SEVERABILITY

 

		7.1	If
                                         any of the provisions in this Deed are found to be invalid, illegal or unenforceable
                                         by any applicable laws, regulations or competent courts, such invalidity, illegality
                                         and unenforceability shall not affect the remaining provisions of this Deed.

 

		8.	GOVERNING
                                         LAW AND DISPUTE RESOLUTION

 

This Deed
shall be governed by and construed in accordance with the laws of Hong Kong Special Administrative Region, and any conflict or
dispute arising from or related to this Deed shall be subject to the non-exclusive jurisdiction of the Hong Kong courts.

 

    8

     

    

 

IN WITNESS
WHEREOF, the undersigned, intending to be legally bound, have duly executed and delivered this Deed to become effective as of
the date first above written.

 

	SIGNED, SEALED AND DELIVERED	)	 
	By	)	 
	AU, SIK KEE (區錫機)	)	/s/
    Sik Kee Au
	Holder of Hong
    Kong Identity Card No.	)	 
	HKID No. K763****	)	 

 

	in the
    presence of :-	/s/
    Mandy Au

 

	SIGNED with the Common Seal
    of	)	 
	REGENCELL BIOSCIENCE	)	 
	LIMITED (腦再生科技有限公司)	)	/s/
    Yat-Gai Au
	and SIGNED by its Director(s)	)	 

 

	in the
    presence of :-	/s/
    James Wai Hong Chung

 

 

9Exhibit
10.2

 

AMENDED
AND RESTATED EMPLOYMENT AGREEMENT 

 

This
AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement” or “Amendment”), is entered
into as of February 2, 2021, by and between Regencell Bioscience Holdings Limited, incorporated under the laws of the Cayman Islands
(the “Company”), and Yat-Gai Au, a holder of Hong Kong Identity Card Number ******** (the “Executive”).
Except with respect to the direct employment of the Executive by the Company, the term “Company” as used herein with
respect to all obligations of the Executive hereunder shall be deemed to include the Company and all of its subsidiaries and affiliated
entities (collectively, the “Group”).

 

RECITALS

 

A.
The Company desires to employ the Executive as its Chief Executive Officer and to assure itself of the services of the Executive
during the term of Employment (as defined below).

 

B.
The Executive desires to be employed by the Company as its Chief Executive Officer during the term of Employment and upon the
terms and conditions of this Agreement.

 

C.
The parties entered into an employment agreement, dated as of November 12, 2020 (the “Original Agreement”).

 

D.
The parties desire to amend and restate Original Agreement to reflect the change of the compensation as described in this Amendment.

 

E.
Section 16 of the Original Agreement provides that the Original Agreement may not be amended, modified or changed (in whole or
in part), except by a formal, definitive written agreement expressly referring to the Original Agreement, which agreement is executed
by both of the parties hereto. This Amendment is intended to evidence the written agreement of each of the parties to amend and
restate the Original Agreement set forth herein.

 

AGREEMENT

 

The
parties hereto agree as follows:

 

	1.	POSITION

 

The
Executive hereby accepts a position of Chief Executive Officer (the “Employment”) of the Company.

 

	2.	TERM

 

	 	Subject
    to the terms and conditions of this Agreement, the initial term of the Employment shall be three (3) years, commencing on
    the effective date of the Company’s registration statement with the U.S. Securities and Exchange Commission (the “Effective
    Date”), unless terminated earlier pursuant to the terms of this Agreement. The Employment will be renewed automatically
    for additional 3-year terms if neither the Company nor the Executive provides a 1-month prior written notice of termination
    of the Employment to the other party, or otherwise proposes to renegotiate the terms of the Employment with the other party
    within three (3) months prior to the expiration of the applicable term, or unless the Employment is terminated earlier pursuant
    to the terms of this Agreement.

 

	3.	DUTIES
    AND RESPONSIBILITIES

 

	 	(a)	The
    Executive’s duties at the Company will include all jobs assigned by the Company’s Board of the Directors (the
    “Board”).

 

	 	(b)	The
    Executive shall devote all of his working time, attention and skills to the performance of his duties at the Company and shall
    faithfully and diligently serve the Company in accordance with this Agreement, the Memorandum and Articles of Association
    of the Company, as amended and restated from time to time (the “Charter Documents”), and the guidelines, policies
    and procedures of the Company approved from time to time by the Board.

 

    1

     

    

 

	 	(c)	The
Executive shall use his best efforts to perform his duties hereunder. The Executive shall not, without the prior written consent
of the Board, become an employee of any entity other than the Company and any subsidiary or affiliate of the Company, and shall
not be concerned or interested in any business or entity that engages in the same business in which the Company engages (any such
business or entity, a “Competitor”), provided that nothing in this clause shall preclude the Executive from holding
any shares or other securities of any Competitor that is listed on any securities exchange or recognized securities market anywhere
if such shares or securities represent less than 5% of the competitors outstanding shares and securities. The Executive shall
notify the Company in writing of his interest in such shares or securities in a timely manner and with such details and particulars
as the Company may reasonably require.

  

	4.	NO
    BREACH OF CONTRACT

 

The
Executive hereby represents to the Company that: (i) the execution and delivery of this Agreement by the Executive and the
performance by the Executive of the Executive’s duties hereunder shall not constitute a breach of, or otherwise contravene,
the terms of any other agreement or policy to which the Executive is a party or otherwise bound, except for agreements entered
into by and between the Executive and any member of the Group pursuant to applicable law, if any; (ii) that the Executive
has no information (including, without limitation, confidential information and trade secrets) relating to any other person or
entity which would prevent, or be violated by, the Executive entering into this Agreement or carrying out his duties hereunder;
(iii) that the Executive is not bound by any confidentiality, trade secret or similar agreement (other than this) with any
other person or entity except for other member(s) of the Group, as the case may be.

 

	5.	Intentionally
Omitted

  

	6.	COMPENSATION
    AND BENEFITS

 

	 	(a)	Base
    Salary. The Executive shall receive a base salary of one U.S. dollar (US$1) per year during the employment term set forth
    in section 2, paid on June 30 of each year, and such arrangement is subject to annual review and adjustment by the Board.

 

	 	(b)	Bonus.
    The Executive shall not draw a bonus prior to and during the employment term, and such arrangement is subject to annual review
    and adjustment by the Board.

 

	 	(c)	Equity
    Incentives. To the extent the Company adopts and maintains a share incentive plan, the Executive will be eligible to participate
    in such plan pursuant to the terms thereof as determined by the Board.

 

	 	(d)	Benefits.
    The Executive is eligible for participation in any standard employee benefit plan of the Company that currently exists or
    may be adopted by the Company in the future, including, but not limited to, any retirement plan, life insurance plan, health
    insurance plan and travel/holiday plan.

 

	 	(e)	Expenses.
    The Executive shall be entitled to reimbursement by the Company for all reasonable ordinary and necessary travel and other
    expenses incurred by the Executive in the performance of his duties under this Agreement; provided that he properly accounts
    for such expenses in accordance with the Company’s policies and procedures.
	 	 	 
	 	(f)	Condition to
    Draw Compensation. The Executive shall not draw the compensation and benefits set forth in this section more than US$1
    unless the Company reaches US$1billion market capitalization, and such arrangement is subject to annual review and adjustment
    by the Board.

 

    2

     

    

 

	7.	TERMINATION
    OF THE AGREEMENT

 

	 	(a)	By
    the Company.

 

(i) For
Cause. The Company may terminate the Employment for cause, at any time, without notice or remuneration (unless notice or remuneration
is specifically required by applicable law, in which case notice or remuneration will be provided in accordance with applicable
law), if:

 

(1)
the Executive is convicted or pleads guilty to a felony or to an act of fraud, misappropriation or embezzlement;

 

(2)
the Executive has been grossly negligent or acted dishonestly to the detriment of the Company;

 

(3)
the Executive has engaged in actions amounting to willful misconduct or failed to perform his duties hereunder and such failure
continues after the Executive is afforded a reasonable opportunity to cure such failure; or

 

(4)
the Executive violates Section 8 or 10 of this Agreement.

 

Upon
termination for cause, the Executive shall be entitled to the amount of base salary earned and not paid prior to termination.
However, the Executive will not be entitled to receive payment of any severance benefits or other amounts by reason of the termination,
and the Executive’s right to all other benefits will terminate, except as required by any applicable law.

 

(ii) For
death and disability. The Company may also terminate the Employment, at any time, without notice or remuneration (unless notice
or remuneration is specifically required by applicable law, in which case notice or remuneration will be provided in accordance
with applicable law), if:

 

(1)
the Executive has died, or

 

(2)
the Executive has a disability which shall mean a physical or mental impairment which, as reasonably determined by the Board,
renders the Executive unable to perform the essential functions of his employment with the Company, with or without reasonable
accommodation, for more than 120 days in any 12-month period, unless a longer period is required by applicable law, in which case
that longer period would apply.

 

Upon
termination for death or disability, the Executive shall be entitled to the amount of base salary earned and not paid prior to
termination. However, the Executive will not be entitled to receive payment of any severance benefits or other amounts by reason
of the termination, and the Executive’s right to all other benefits will terminate, except as required by any applicable
law.

 

(iii) Without
Cause. The Company may terminate the Employment without cause, at any time, upon one-month prior written notice. Upon termination
without cause, the Company shall provide the following severance payments and benefits to the Executive: (1) a lump sum cash
payment equal to 1 months of the Executive’s base salary as of the date of such termination; (2) a lump sum cash payment
equal to a pro-rated amount of his target annual bonus for the year immediately preceding the termination, if any; (3) payment
of premiums for continued health benefits under the Company’s health plans for 12 months fo1lowing the termination, if any;
and (4) immediate vesting of 100% of the then-unvested portion of any outstanding equity awards held by the Executive.

 

Upon
termination without cause, the Executive shall be entitled to the amount of base salary earned and not paid prior to termination.

 

(iv) Change
of Control Transaction. If the Company or its successor terminates the Employment upon a merger, consolidation, or transfer
or sale of all or substantially all of the assets of the Company with or to any other individual(s) or entity (the “Change
of Control Transaction”), the Executive shall be entitled to the following severance payments and benefits upon such
termination: (1) a lump sum cash payment equal to 1 months of the Executive’s base salary at a rate equal to the greater
of his/her annual salary in effect immediately prior to the termination, or his/her then current annua1 salary as of the date
of such termination; (2) a lump sum cash payment equal to a pro-rated amount of his/her target annual bonus for the year
immediately preceding the termination; (3) payment of premiums for continued health benefits under the Company’s health
plans for 12 months fo1lowing the termination; and (4) immediate vesting of 100% of the then-unvested portion of any outstanding
equity awards held by the Executive.

 

    3

     

    

 

	 	(b)	By
    the Executive. The Executive may terminate the Employment at any time with a one-month prior written notice to the Company,
    if (1) there is a material reduction in the Executive’s authority, duties and responsibilities, or (2) there
    is a material reduction in the Executive’s annual salary. Upon the Executive’s termination of the Employment due
    to either of the above reasons, the Company shall provide compensation to the Executive equivalent to 1 months of the Executive’s
    base salary that he is entitled to immediately prior to such termination. In addition, the Executive may resign prior to the
    expiration of the Agreement if such resignation is approved by the Board or an alternative arrangement with respect to the
    Employment is agreed to by the Board.

 

	 	(c)	Notice
    of Termination. Any termination of the Executive’s employment under this Agreement shall be communicated by
    written notice of termination from the terminating party to the other party. The notice of termination shall indicate the
    specific provision(s) of this Agreement relied upon in effecting the termination.

 

	8.	CONFIDENTIALITY
    AND NON-DISCLOSURE

 

	 	(a)	Confidentiality
    and Non-disclosure. The Executive hereby agrees at all times during the term of the Employment, to hold in the strictest
    confidence, and not to use, except for the benefit of the Company, or to disclose to any person, corporation or other entity
    without prior written consent of the Company, any Confidential Information. The Executive understands that “Confidential
    Information” means any proprietary or confidential information of the Company, its affiliates, or their respective
    clients, customers or partners, including, without limitation, technical data, trade secrets, research and development information,
    product plans, services, customer lists and customers, supplier lists and suppliers, software developments, inventions, processes,
    formulas, technology, designs, hardware configuration information, personnel information, marketing, finances, information
    about the suppliers, joint ventures, franchisees, distributors and other persons with whom the Company does business, information
    regarding the skills and compensation of other employees of the Company or other business information disclosed to the Executive
    by or obtained by the Executive from the Company, its affiliates, or their respective clients, customers or partners, either
    directly or indirectly, in writing, orally or otherwise, if specifically indicated to be confidential or reasonably expected
    to be confidential. The confidentiality obligations under this Clause shall survive notwithstanding the termination of this
    Employment Agreement for ten (10) years thereafter. Notwithstanding the foregoing, Confidential Information shall not include
    information that is generally available and known to the public through no fault of the Executive.

 

	 	(b)	Company
    Property. The Executive understands that all documents (including computer records, facsimile and e-mail) and materials
    created, received or transmitted in connection with his work or using the facilities of the Company are property of the Company
    and subject to inspection by the Company at any time. Upon termination of the Executive’s employment with the Company
    (or at any other time when requested by the Company), the Executive will promptly deliver to the Company all documents and
    materials of any nature pertaining to his work with the Company and will provide written certification of his compliance with
    this Agreement. Under no circumstances will the Executive have, following his termination, in his possession any property
    of the Company, or any documents or materials or copies thereof containing any Confidential Information.

 

	 	(c)	Former
    Employer Information. The Executive agrees that he has not and will not, during the term of his employment, (i) improperly
    use or disclose any proprietary information or trade secrets of any former employer or other person or entity with which the
    Executive has an agreement or duty to keep in confidence information acquired by Executive, if any, or (ii) bring into
    the premises of the Company any document or confidential or proprietary information belonging to such former employer, person
    or entity unless consented to in writing by such former employer, person or entity. The Executive will indemnify the Company
    and hold it harmless from and against all claims, liabilities, damages and expenses, including reasonable attorneys’
    fees and costs of suit, arising out of or in connection with any violation of the foregoing.

 

	 	(d)	Third
    Party Information. The Executive recognizes that the Company may have received, and in the future may receive, from third
    parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality
    of such information and to use it only for certain limited purposes. The Executive agrees that the Executive owes the Company
    and such third parties, during the Executive’s employment by the Company and thereafter, a duty to hold all such confidential
    or proprietary information in the strictest confidence and not to disclose it to any person or firm and to use it in a manner
    consistent with, and for the limited purposes permitted by, the Company’s agreement with such third party.

  

This
Section 8 shall survive the termination of this Agreement for any reason. In the event the Executive breaches this Section 8,
the Company shall have right to seek remedies permissible under applicable law.

 

    4

     

    

 

	9.	CONFLICTING
    EMPLOYMENT

 

The
Executive hereby agrees that, during the term of his employment with the Company, he will not engage in any other employment,
occupation, consulting or other business activity related to the business in which the Company is now involved or becomes involved
during the term of the Executive’s employment, nor will the Executive engage in any other activities that conflict with
his obligations to the Company without the prior written consent of the Company.

 

	10.	NON-COMPETITION
AND NON-SOLICITATION

 

In
consideration of the compensation and benefits paid to the Executive by the Company and subject to applicable law, the Executive
agrees that during the term of the Employment and for a period of two (2) years following the termination of the Employment for
whatever reason:

 

	 	(a)	The
    Executive will not approach clients, customers or contacts of the Company or other persons or entities introduced to the Executive
    in the Executive’s capacity as a representative of the Company for the purposes of doing business with such persons
    or entities which will harm the business relationship between the Company and such persons and/or entities;

 

	 	(b)	The
    Executive will not assume employment with or provide services as a director or otherwise for any Competitor, or engage, whether
    as principal, partner, licensor or otherwise, in any Competitor; and

 

	 	(c)	The
    Executive will not seek, directly or indirectly, by the offer of alternative employment or other inducement whatsoever, to
    solicit the services of any employee of the Company employed as at or after the date of such termination, or in the year preceding
    such termination.

 

The
provisions contained in Section 10 are considered reasonable by the Executive and the Company. In the event that any such
provisions should be found to be void under applicable laws but would be valid if some part thereof was deleted or the period
or area of application reduced, such provisions shall apply with such modification as may be necessary to make them valid and
effective.

 

This
Section 10 shall survive two (2) years after the termination of this Agreement for any reason. In the event the Executive breaches
this Section 10, the Executive acknowledges that there will be no adequate remedy at law, and the Company shall be entitled to
injunctive relief and/or a decree for specific performance, and such other relief as may be proper (including monetary damages
if appropriate). In any event, the Company shall have right to seek all remedies permissible under applicable law.

 

	11.	WITHHOLDING
TAXES

 

Notwithstanding
anything else herein to the contrary, the Company may withhold (or cause there to be withheld, as the case may be) from any amounts
otherwise due or payable under or pursuant to this Agreement such national, provincial, local or any other income, employment,
or other taxes as may be required to be withheld pursuant to any applicable law or regulation.

 

	12.	ASSIGNMENT

 

This
Agreement is personal in its nature and neither of the parties hereto shall, without the consent of the other, assign or transfer
this Agreement or any rights or obligations hereunder; provided, however, that (i) the Company may assign or transfer this
Agreement or any rights or obligations hereunder to any member of the Group without such consent, and (ii) in the event of
a Change of Control Transaction, this Agreement shall, subject to the provisions hereof, be binding upon and inure to the benefit
of such successor and such successor shall discharge and perform all the promises, covenants, duties, and obligations of
the Company hereunder.

 

    5

     

    

 

	13.	SEVERABILITY

 

If
any provision of this Agreement or the application thereof is held invalid, the invalidity shall not affect other provisions or
applications of this Agreement which can be given effect without the invalid provisions or applications and to this end the provisions
of this Agreement are declared to be severable.

 

	14.	 ENTIRE
    AGREEMENT

 

This
Agreement constitutes the entire agreement and understanding between the Executive and the Company regarding the terms of the
Employment and supersedes all prior or contemporaneous oral or written agreements concerning such subject matter, including any
prior agreements between the Executive and a member of the Group. The Executive acknowledges that he has not entered into this
Agreement in reliance upon any representation, warranty or undertaking which is not set forth in this Agreement. Any amendment
to this Agreement must be in writing and signed by the Executive and the Company.

 

	15.	GOVERNING
LAW; JURISDICTION

 

This
Agreement shall be governed by and construed in accordance with the laws of Hong Kong and each of the parties irrevocably consents
to the jurisdiction and venue of the courts located in Hong Kong.

 

	16.	AMENDMENT

 

This
Agreement may not be amended, modified or changed (in whole or in part), except by a formal, definitive written agreement expressly
referring to this Agreement, which agreement is executed by both of the parties hereto.

 

	17.	WAIVER

 

Neither
the failure nor any delay on the part of a party to exercise any right, remedy, power or privilege under this Agreement shall
operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege preclude any other
or further exercise of the same or of any right, remedy, power or privilege, nor shall any waiver of any right, remedy, power
or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with respect to
any other occurrence. No waiver shall be effective unless it is in writing and is signed by the party asserted to have granted
such waiver.

 

	18.	NOTICES

 

All
notices, requests, demands and other communications required or permitted under this Agreement shall be in writing and shall be
deemed to have been duly given and made if (i) delivered by hand, (ii) otherwise delivered against receipt therefor,
or (iii) sent by a recognized courier with next-day or second-day delivery to the last known address of the other party.

 

	19.	COUNTERPARTS

 

This
Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against any party whose
signature appears thereon, and all of which together shall constitute one and the same instrument. This Agreement shall become
binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties
reflected hereon as the signatories.

 

Photographic
copies of such signed counterparts may be used in lieu of the originals for any purpose.

 

	20.	NO
INTERPRETATION AGAINST DRAFTER

 

Each
party recognizes that this Agreement is a legally binding contract and acknowledges that he has had the opportunity to consult
with legal counsel of choice. In any construction of the terms of this Agreement, the same shall not be construed against either
party on the basis of that party being the drafter of such terms.

 

[Remainder
of this page has been intentionally left blank.]

 

    6

     

    

 

 

IN
WITNESS WHEREOF, this Agreement has been executed as of the date first written above.

 

	 	Regencell Bioscience Holdings
    Limited
	 

         
	By:
	

        /s/
        Yi-Chung Chao

	 	Name:	Yi-Chung Chao    
	 	Title:	Chief Medical Officer    

 

	 	Executive
	 	
	 
	 	Signature:	/s/
    Yat-Gai Au
	 	Name:	Yat-Gai Au

 

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]